The Role of the Circadian Clock in Fat Body Transcriptomics and Metabolomics

Drosophila melanogaster circadian rhythms oscillate based on many different factors and are dictated by the central brain clock, input pathways that take in outside information, and output pathways. These output pathways include peripheral tissues that can affect many different behaviors. An example of one of these tissues is the fat body, which may play a role in feeding/fasting rhythms. The mechanism used to control this behavior is not well known. By determining a connection between the central brain clock and peripheral tissues such as the fat body, the way that physiological processes such as metabolism, energy storage, and behavioral outputs are controlled can be better understood. Long term, this project aims to identify connections between metabolic rhythms utilizing metabolomics and transcriptomic of the fat body. To do so, the best, most specific driver with which to manipulate the fat body must be identified, and the expression of any other tissues must be identified. Using the GAL4-UAS system, the manipulation or selective inactivation of fat body tissues can be accomplished by certain drivers. Takeout-GAL4 is well-known as a fat body driver but may show expression in other tissues which must be identified in more detail. Lsp is another driver that must be characterized and compared to Takeout-GAL4. By characterizing each driver in detail, the most selective one can be utilized in later experiments to learn more about circadian relation to metabolism

The Ursinus Weekly, February 7, 1944

Sally Deibler sells $1400 in bonds as fourth loan drive reaches new high • Loughead charms top crowd at festive quarterdeck hop • Typical student is quiet and reserved at Ursinus College • Dr. James Dean gives talk on central nervous system • Cap is aiding war effort, seeks air-minded recruits • French Club will feature songs, games at meeting • Joh Ziegler addresses student body at vespers • Community club plans public forum on labor relations topic, Feb. 8 • Y party to feature ace novelty act • Don\u27t be be a Joe or Maisie Zilch, try studying now for those exams • Phys-edders meet tonight • Perkiomen AAUW to hear speech on four freedoms • Ursinus debaters to meet Kutztown team tomorrow • War prisoners receive thousands of books • Improved girls\u27 team defeats Albright, Rosemont sextettes • Juniata downs bears in close contest, 64-52 • Hauser and Moore set pace as bears take Swarthmore • Lynnewood downs south in first inter-dorm game • Ursinus wrestlers to meet Muhlenberg this Saturday • Jack Bradford has sandwich shop where the elite meet to eat - meathttps://digitalcommons.ursinus.edu/weekly/1724/thumbnail.jp

Columbus State University Honors College: Senior Theses, Fall 2019

This is a collection of senior theses written by honors students at Columbus State University in 2019.https://csuepress.columbusstate.edu/honors_theses/1000/thumbnail.jp

A sensitive high performance liquid chromatography assay for the quantification of doxorubicin associated with DNA in tumor and tissues

A HPLC method was validated to quantify doxorubicin associated to DNA from tissue.Successfully applied to an in vivo mouse-based pharmacokinetic study.Important tool for future studies evaluating intracellular pharmacokinetics.Doxorubicin, a widely used anticancer agent, exhibits antitumor activity against a wide variety of malignancies. The drug exerts its cytotoxic effects by binding to and intercalating within the DNA of tumor and tissue cells. However, current assays are unable to accurately determine the concentration of the intracellular active form of doxorubicin. Thus, the development of a sample processing method and a high-performance liquid chromatography (HPLC) methodology was performed in order to quantify doxorubicin that is associated with DNA in tumors and tissues, which provided an intracellular cytotoxic measure of doxorubicin exposure after administration of small molecule and nanoparticle formulations of doxorubicin. The assay uses daunorubicin as an internal standard; liquid–liquid phase extraction to isolate drug associated with DNA; a Shimadzu HPLC with fluorescence detection equipped with a Phenomenex Luna C18 (2 μm, 2.0 × 100 mm) analytical column and a gradient mobile phase of 0.1% formic acid in water or acetonitrile for separation and quantification. The assay has a lower limit of detection (LLOQ) of 10 ng/mL and is shown to be linear up to 3000 ng/mL. The intra- and inter-day precision of the assay expressed as a coefficient of variation (CV%) ranged from 4.01 to 8.81%. Furthermore, the suitability of this assay for measuring doxorubicin associated with DNA in vivo was demonstrated by using it to quantify the doxorubicin concentration within tumor samples from SKOV3 and HEC1A mice obtained 72 h after administration of PEGylated liposomal doxorubicin (Doxil®; PLD) at 6 mg/kg IV x 1. This HPLC assay allows for sensitive intracellular quantification of doxorubicin and will be an important tool for future studies evaluating intracellular pharmacokinetics of doxorubicin and various nanoparticle formulations of doxorubicin

The Ursinus Weekly, January 10, 1944

Fine cast chosen for coming play, Jupiter Laughs • Ensign Miriam Waltemyer to speak on Navy waves • Senator Ball will speak at Ursinus this Wednesday on post-war world • Ursinus honor grad to speak tonight • Dorothy Waltz engaged • Intersorority dance postponed • Students joyful at belated banquet • Rosicrucians elect girls to fill coveted offices • Memorial marks site of girls\u27 seminary • Post-war employment ideas solicited in Pabst contest • Dr. Hartzell holds office on Collegeville council • Combined Y\u27s will sponsor amateur night on Friday • Rev. Shaffer addresses student body at vespers • Ursinus students speak • Publishers offer awards to writers in services • German Club features sing • James Boswell to teach mathematics at Illinois • Leona Miller to give make-up demonstration • Captain Fury presented • Loraine Walton to review Taps for Private Tussie • The librarian\u27s angle • Courtmen lose close tilt to F. & M. when Mackin scores in last minute • Garnet crushes Ursinus grapplers • Carney beats Shope in intramural games • Men\u27s varsity defeats Valley Forge hospital • Five girls return from 1943 varsity • Freshman receives rating in 1943 tennis lineup • Basketball five downs Superior Tube team • War cannot stop Russian colleges • Ursinus students flock to Thompson-Gay gymhttps://digitalcommons.ursinus.edu/weekly/1722/thumbnail.jp

N- to C-sulfonyl photoisomerisation of dihydropyridinones : a synthetic and mechanistic study

The authors thank the European Research Council under the European Union’s Seventh Framework Programme (FP7/2007–2013) ERC Grant Agreement no. 279850 (CF and JET) and EPSRC grant number EP/J018139/1 (DSBD) for funding. ADS thanks the Royal Society for a Wolfson Research Merit Award.The scope and limitations of a photoinitiated N- to C-sulfonyl migration process within a range of dihydropyridinones is assessed. This sulfonyl transfer proceeds without erosion of either diastereo- or enantiocontrol, and is general across a range of N-sulfonyl substituents (SO2R; R = Ph, 4-MeC6H4, 4-MeOC6H4, 4-NO2C6H4, Me, Et) as well as C(3)-(aryl, heteroaryl, alkyl and alkenyl) and C(4)-(aryl and ester) substitution. Crossover reactions indicate an intermolecular step is operative within the formal migration process, although no crossover from C-sulfonyl products was observed. EPR studies indicate the intermediacy of a sulfonyl radical and a mechanism is proposed based upon these observations.Publisher PDFPeer reviewe

Is it safe to move away from a full sternotomy for aortic valve replacement?

Minimally invasive surgical approaches have gained popularity among patients and surgeons. The aim of this project was to assess the safety of initiating aortic valve replacement via an anterior right thoracotomy program

The Lantern Vol. 14, No. 2, February 1946

• Dog Daze • Locomotion • The Battle • Thoughts at Midnight • We Have a Race to Run • A Parable • Darkness at Dawn • Room for Error • Elegy Americana • Will This Happen Here • Last Mission • Free Trade • Love Letterhttps://digitalcommons.ursinus.edu/lantern/1038/thumbnail.jp

Exercise-based cardiac rehabilitation for adults with heart failure

Background Chronic heart failure (HF) is a growing global health challenge. People with HF experience substantial burden that includes low exercise tolerance, poor health-related quality of life (HRQoL), increased risk of mortality and hospital admission, and high healthcare costs. The previous (2014) Cochrane systematic review reported that exercise-based cardiac rehabilitation (CR) compared to no exercise control shows improvement in HRQoL and hospital admission among people with HF, as well as possible reduction in mortality over the longer term, and that these reductions appear to be consistent across patient and programme characteristics. Limitations noted by the authors of this previous Cochrane Review include the following: (1) most trials were undertaken in patients with HF with reduced (< 45%) ejection fraction (HFrEF), and women, older people, and those with preserved (≥ 45%) ejection fraction HF (HFpEF) were under-represented; and (2) most trials were undertaken in the hospital/centre-based setting. Objectives To determine the effects of exercise-based cardiac rehabilitation on mortality, hospital admission, and health-related quality of life of people with heart failure. Search methods We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, and three other databases on 29 January 2018. We also checked the bibliographies of systematic reviews and two trial registers. Selection criteria We included randomised controlled trials that compared exercise-based CR interventions with six months’ or longer follow-up versus a no exercise control that could include usual medical care. The study population comprised adults (> 18 years) with evidence of HF - either HFrEF or HFpEF. Data collection and analysis Two review authors independently screened all identified references and rejected those that were clearly ineligible for inclusion in the review. We obtained full papers of potentially relevant trials. Two review authors independently extracted data from the included trials, assessed their risk of bias, and performed GRADE analyses. Main results We included 44 trials (5783 participants with HF) with a median of six months’ follow-up. For this latest update, we identified 11 new trials (N = 1040), in addition to the previously identified 33 trials. Although the evidence base includes predominantly patients with HFrEF with New York Heart Association classes II and III receiving centre-based exercise-based CR programmes, a growing body of studies include patients with HFpEF and are undertaken in a home-based setting. All included studies included a no formal exercise training intervention comparator. However, a wide range of comparators were seen across studies that included active intervention (i.e. education, psychological intervention) or usual medical care alone. The overall risk of bias of included trials was low or unclear, and we downgraded results using the GRADE tool for all but one outcome. Cardiac rehabilitation may make little or no difference in all-cause mortality over the short term (≤ one year of follow-up) (27 trials, 28 comparisons (2596 participants): intervention 67/1302 (5.1%) vs control 75/1294 (5.8%); risk ratio (RR) 0.89, 95% confidence interval (CI) 0.66 to 1.21; low-quality GRADE evidence) but may improve all-cause mortality in the long term (> 12 months follow up) (6 trials/comparisons (2845 participants): intervention 244/1418 (17.2%) vs control 280/1427 (19.6%) events): RR 0.88, 95% CI 0.75 to 1.02; high-quality evidence). Researchers provided no data on deaths due to HF. CR probably reduces overall hospital admissions in the short term (up to one year of follow-up) (21 trials, 21 comparisons (2182 participants): (intervention 180/1093 (16.5%) vs control 258/1089 (23.7%); RR 0.70, 95% CI 0.60 to 0.83; moderate-quality evidence, number needed to treat: 14) and may reduce HF-specific hospitalisation (14 trials, 15 comparisons (1114 participants): (intervention 40/562 (7.1%) vs control 61/552 (11.1%) RR 0.59, 95% CI 0.42 to 0.84; low-quality evidence, number needed to treat: 25). After CR, a clinically important improvement in shortterm disease-specific health-related quality of life may be evident (Minnesota Living With Heart Failure questionnaire - 17 trials, 18 comparisons (1995 participants): mean difference (MD) -7.11 points, 95% CI -10.49 to -3.73; low-quality evidence). Pooling across all studies, regardless of the HRQoL measure used, shows there may be clinically important improvement with exercise (26 trials, 29 comparisons (3833 participants); standardised mean difference (SMD) -0.60, 95% CI -0.82 to -0.39; I² = 87%; Chi² = 215.03; lowquality evidence). ExCR effects appeared to be consistent different models of ExCR delivery: centre vs. home-based, exercise dose, exercise only vs. comprehensive programmes, and aerobic training alone vs aerobic plus resistance programmes. Authors’ conclusions This updated Cochrane Review provides additional randomised evidence (11 trials) to support the conclusions of the previous version (2014) of this Cochane Review. Compared to no exercise control, CR appears to have no impact on mortality in the short term (< 12 months’ follow-up). Low- to moderate-quality evidence shows that CR probably reduces the risk of all-cause hospital admissions and may reduce HF-specific hospital admissions in the short term (up to 12 months). CR may confer a clinically important improvement in health-related quality of life, although we remain uncertain about this because the evidence is of low quality. Future ExCR trials need to continue to consider the recruitment of traditionally less represented HF patient groups including older, female, and HFpEF patients, and alternative CR delivery settings including home- and using technology-based programmes